LA JOLLA, Calif., July 29, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a non-exclusive co-promotion agreement with Consortia Health Clinical Continence Services, LLC ("Consortia"). Under the agreement, Consortia will market Innovus Pharma's product for premature ejaculation, EjectDelay, in the states of the United States, where Consortia has commercial reach and presence. Consortia will target urologists and sex therapists in its co-promotion efforts and Innovus Pharma will pay Consortia a co-promotion fee based on a percentage of the net sales of EjectDelay to Consortia's targeted physicians and their patients.
In addition, Innovus Pharma is building its sales force in the states not covered by Consortia sales representatives. Robert Verfurth, Vice President of Sales and Marketing, commented, "The combination of Consortia's and our sales forces, once fully recruited, will potentially give us a national presence in the US and allow us to carry additional urology products."
Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma, commented, "We are very excited about this co-promotion agreement with Consortia and we look forward to expanding the reach of our EjectDelay product in the United States. This is an important milestone in our strategy to make EjectDelay available to urologists and sex therapists and show the successful continuation of the execution of our commercialization strategy of the Company."
About EjectDelay and Premature Ejaculation
EjectDelay is an OTC FDA compliant proprietary topical treatment containing the drug benzocaine. It is indicated for delay of premature ejaculation. The drug works within minutes of application to the glans of the penis. For more information visit www.ejectdelay.com.
Premature ejaculation, or PE, is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007, D.L. Patrick, D. Rowland and M. Rothman stated, "Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe."
About Consortia Health Clinical Continence Services, LLC
Consortia is a urology and gynecology focused medical device provider and service company based in Austin, Texas. The Company is committed to supporting healthcare professionals with identification, diagnosis and treatment of pelvic floor disorders and has assisted thousands of patients and their physicians in more than thirty states and four countries.
For more information, go to www.consortiahealth.com.
About Innovus Pharmaceuticals, Inc.
Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.
For more information, go to www.innovuspharma.com.
Forward-Looking Statements:
With the exception of the historical statements, statements contained in this release, including statements regarding Innovus Pharma's ability to carry additional products and the expansion of the reach of its products, are forward-looking statements. Forward-looking statements are based on current expectations of Innovus Pharma, but are subject to a number of risks, uncertainties and assumptions. You are cautioned not to place undue reliance on forward-looking statements as actual results could differ materially. Risks and uncertainties include, but are not limited to, the company's ability to successfully commercialize its products and others more fully described in the company's press releases and periodic reports filed with the SEC, copies of which are available from the SEC's website (www.sec.gov) or the "Investors" section of www.innovuspharma.com. Forward-looking statements speak only as of the date made. Except as required by law, Innovus Pharma undertakes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.